while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

Sanofi also confirmed the expectation of a strong ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Sanofi (SNY) commits $20B to U.S. research & manufacturing by 2030, boosting R&D & partnerships amidst industry-wide ...

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks Consensus Estimate of 90 cents per share. Earnings of €1.79 per share ...

$2,540,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Drug Pricing - General Issues ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on BioNTech (NASDAQ:BNTX ... Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its ...

Stocks recently featured in the blog include: Gilead Sciences GILD, Bristol Myers BMY, Merck MRK, AbbVie ABBV and Sanofi SNY. Here are highlights from Tuesday’s Analyst Blog: Will These 5 Large ...

Innate Pharma said that Sanofi has announced a 15 million euros ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering ... and bispecific antibodies with Sanofi, other collaborators, and independently ...